CLOPIDOGREL 75mg. IP + ASPIRIN 75mg. IP

A dual antiplatelet therapy that prevents platelet aggregation and cardiovascular events. (Yasuo Takahashi, 2013) Reduces the risk of ischemic events in patients with myocardial infarction and after angioplasty or stenting. (Yasuo Takahashi, 2013) Blocks platelet from sticking together and hinders the formation of harmful clots. More effective than aspirin alone in reducing the risk of stroke without increasing the risk of bleeding events in patients already having an episode of minor stroke. (C, 2015) Protects against major cardiovascular events, myocardial infarction, or stroke as compared to aspirin therapy alone. (Yu-Hao Zhou, 2012) Prevents blood clots in conditions such as atherosclerosis, unstable angina, myocardial infarction, and atrial fibrillation. A potent antiplatelet agent reduces the risk for thrombotic events in patients with atherothrombotic diseases. (Sung-Doo Kim, 2009) A front-line drug in the prevention of arterial thrombosis in high-risk patients, such as those with arterial stents and atherosclerotic disease. (Kallmes, 2011)